| 000 | 01856 a2200541 4500 | ||
|---|---|---|---|
| 005 | 20250513041248.0 | ||
| 264 | 0 | _c19950518 | |
| 008 | 199505s 0 0 eng d | ||
| 022 | _a0022-3751 | ||
| 024 | 7 |
_a10.1113/jphysiol.1995.sp020531 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aCuthbert, A W | |
| 245 | 0 | 0 |
_aThe genetic advantage hypothesis in cystic fibrosis heterozygotes: a murine study. _h[electronic resource] |
| 260 |
_bThe Journal of physiology _cJan 1995 |
||
| 300 |
_a449-54 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aBacterial Toxins _xpharmacology |
| 650 | 0 | 4 |
_aCalcium _xmetabolism |
| 650 | 0 | 4 |
_aCarbachol _xpharmacology |
| 650 | 0 | 4 |
_aChloride Channels _xgenetics |
| 650 | 0 | 4 |
_aCholera Toxin _xpharmacology |
| 650 | 0 | 4 |
_aColforsin _xpharmacology |
| 650 | 0 | 4 |
_aColon _xchemistry |
| 650 | 0 | 4 |
_aCyclic AMP _xmetabolism |
| 650 | 0 | 4 |
_aCystic Fibrosis _xgenetics |
| 650 | 0 | 4 |
_aEnterotoxins _xpharmacology |
| 650 | 0 | 4 |
_aEpithelium _xdrug effects |
| 650 | 0 | 4 | _aEscherichia coli Proteins |
| 650 | 0 | 4 |
_aFurosemide _xpharmacology |
| 650 | 0 | 4 | _aGastrointestinal Hormones |
| 650 | 0 | 4 |
_aGlucose _xpharmacology |
| 650 | 0 | 4 | _aHeterozygote |
| 650 | 0 | 4 |
_aIleum _xphysiology |
| 650 | 0 | 4 |
_aIsoproterenol _xpharmacology |
| 650 | 0 | 4 |
_aKallidin _xpharmacology |
| 650 | 0 | 4 | _aMice |
| 650 | 0 | 4 | _aMice, Mutant Strains |
| 650 | 0 | 4 | _aNatriuretic Peptides |
| 650 | 0 | 4 |
_aPeptides _xpharmacology |
| 650 | 0 | 4 |
_aVasoactive Intestinal Peptide _xpharmacology |
| 700 | 1 | _aHalstead, J | |
| 700 | 1 | _aRatcliff, R | |
| 700 | 1 | _aColledge, W H | |
| 700 | 1 | _aEvans, M J | |
| 773 | 0 |
_tThe Journal of physiology _gvol. 482 ( Pt 2) _gp. 449-54 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1113/jphysiol.1995.sp020531 _zAvailable from publisher's website |
| 999 |
_c7714229 _d7714229 |
||